Breakthrough: FDA Approves First Drug Offering a 'Functional Cure' For Chronic Hepatitis B

Food and Drug Administration issued an approval for Hibsago, the trade name of GSK’s investigational agent bepirovirsen, for the treatment of chronic hepatitis B virus (HBV) infection. Coverage notes that the approval applies to patients with lifelong hepatitis B infection, a condition that has historically required long‑term antiviral suppression rather than eradication. The story was reported across a range of specialty and mainstream outlets. Pharmacy Practice News highlighted the FDA decision, while Dealroom focused on Health Canada’s parallel endorsement and emphasized the functional‑cure label.

The Pharma Letter placed Hibsago among the broader slate of October 2026 FDA approvals, noting its regulatory significance. The Calgary Herald framed the development as a new cure arriving for a chronic disease, and ScienceAlert used the term ‘breakthrough’ to describe the first drug offering a functional cure for hepatitis B. Chronic hepatitis B affects millions worldwide and is typically managed with nucleos(t)ide analogues that suppress viral replication without eliminating the virus from the body. A functional cure, as defined by the approving agencies, refers to sustained loss of hepatitis B surface antigen and durable viral control without the need for ongoing therapy.

Hibsago’s approval therefore represents a shift from suppression to a therapeutic outcome that could reduce lifelong treatment burdens and associated complications. Future coverage will likely track the rollout of Hibsago in the United States and Canada, including incorporation into clinical guidelines and reimbursement decisions. Observers will watch for post‑marketing data that confirm the functional‑cure claim in broader patient populations. Additional regulatory filings in other jurisdictions may follow, and the pharmaceutical market may see competitive activity as other developers pursue similar cure‑oriented approaches.